Production (Stage)
Inhibikase Therapeutics, Inc.
IKT
$1.95
-$0.01-0.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.55M | -27.52M | -19.57M | -18.38M | -19.20M |
| Total Depreciation and Amortization | 32.50K | 26.40K | 26.40K | 26.40K | 179.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.32M | 8.14M | 368.60K | 367.70K | 461.80K |
| Change in Net Operating Assets | 810.30K | 205.00K | 1.93M | 1.52M | 2.58M |
| Cash from Operations | -19.38M | -19.15M | -17.24M | -16.47M | -15.98M |
| Capital Expenditure | -13.40K | -- | 0.00 | 0.00 | -14.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -12.62M | -37.00M | -358.10K | 14.18M | 14.20M |
| Cash from Investing | -12.64M | -37.00M | -358.10K | 14.18M | 14.18M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 103.08M | 103.48M | 3.79M | 3.61M | 398.20K |
| Repurchase of Common Stock | -- | -- | -- | -- | -36.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 30.60K | 0.00 | -138.60K | -138.60K | -169.20K |
| Cash from Financing | 103.11M | 103.48M | 3.66M | 3.47M | 193.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.09M | 47.33M | -13.95M | 1.18M | -1.60M |